Promimic (PRO.ST) Stock Analysis & AI Equity Report
Promimic (PRO.ST) overview
Promimic (PRO.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Promimic reported revenue of SEK 44.4m and operating profit of SEK -7.6m; the year-end share price was 16.95 SEK and market capitalisation was SEK 320m. Promimic is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Promimic's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Promimic
Promimic AB (publ) develops and commercializes biomaterial surface treatments for medical implants. Its HA nano Surface technology is applied to implant materials to improve osseointegration, and the company works with medical device manufacturers in dental and orthopedic markets. It also supports production and commercialization through partners and its US operations.
Generate the Promimic report
Promimic is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Promimic and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.